Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
45.25    2.75 (6.47%)
Bid:
44.50
Ask:
46.00
Spread: 1.50 (3.371%)
Market Cap: £86.82m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

Debt Restructuring

12 Feb 2019 07:00

RNS Number : 6963P
Iofina PLC
12 February 2019
 

 

12 February 2019

Iofina plc

("Iofina", the "Group", or the "Company")

(LSE AIM: IOF)

 

Debt Restructuring

 

Extension of Term and Removal of Debt Convertibility

 

Iofina, specialists in the exploration and production of iodine and halogen-based specialty chemical derivatives, is pleased to announce it has entered into a Memorandum of Understanding with its Noteholders to restructure the convertible loan notes previously issued to them (the 'Notes'). Additionally, the Term Loan Facility (the 'Facility') provided by Stena Investment S.á.r.l. ('Stena') has also been restructured. Further details relating to the Noteholders, the Notes and the Facility are set out in the Company's announcement dated 30 September 2016. This restructuring is subject to finalised documentation and will be completed as soon as practical. The Group is now better positioned to build upon last year's improved performance with increased profitability for 2019 and beyond.

 

 

The new terms are as follows:

 

Notes:

· Extension of repayment term to 1 July 2020

· Removal of debt convertibility with Notes switching to a term loan

· Interest rate adjusted to 7.5% beginning 1 January 2019

· Interest paid to Noteholders quarterly in arrears beginning in 2019

 

Facility:

· Extension of repayment term to 1 July 2020

· Interest rate adjusted to 7.5% beginning 1 January 2019, rising to 12% on 1 June 2019

· Interest paid to Stena quarterly in arrears beginning in 2019

 

Debt as at 31 December 2018 was comprised approximately of:

· $22.37m under Notes

· $3.26m under Facility

 

Other existing provisions relating to the Notes and the Facility continue in effect. In particular, all debt may be repaid in whole or in part at any time without penalty, the Facility is to be repaid in priority to the Notes, and the entirety of the debt is secured against the assets of the Group.

 

The extension of the debt, along with the removal of the convertibility of the Notes, is an important step forward for Iofina and its shareholders. The Directors appreciate the continued support of our long-term finance partners, with the collective goal for Iofina to continue to expand its operations and increase profits. Iofina is now well positioned to continue to execute business objectives during this time of increasing iodine prices and global demand for iodine.

 

 

 

 

Commenting, President and CEO Dr. Tom Becker stated: ''Extending the terms of the Notes and Facility to 1 July 2020 will allow us to continue upgrading and expanding our plants, which in turn will further boost the level of Iodine production. At the same time the removal of the debt convertibility is a huge positive for our shareholders. With iodine prices continuing to rise we are well positioned to continue the momentum built over the last few years."

 

Enquiries:

 

Dr. Tom Becker, CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

 

Christopher Raggett/Giles Rolls/Anthony Adams

finnCap Ltd

Tel: +44 (0)20 7220 0500

 

Media Contact:

Charles Goodwin/Harriet Jackson

Yellow Jersey PR Limited

Tel: +44 (0)7544 275 882

About Iofina:

Iofina specialises in the exploration and production of iodine, halogen based specialty chemical derivatives and produced water. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America, based on Iofina's WET® IOsorb® technology. Iofina has production operations in the United States, specifically in Kentucky and Oklahoma. It is a vertically integrated company, covering the process from the production of iodine in the field, to the manufacture of the chemical end-products derived from iodine, supplying them to the consumer, and the recycling of iodine using iodinated side-streams from waste chemical processes. Iofina utilises its portfolio of patented and patent-pending technology, and proprietary methods and trademarks throughout all business lines.

www.iofina.com

 

THE INFORMATION COMMUNICATED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCGGUACPUPBPUG
Date   Source Headline
9th May 20237:00 amRNSNotice of AGM
4th May 20237:00 amRNSInvestor Presentation
28th Apr 20234:45 pmRNSHolding(s) in Company
28th Apr 20237:00 amRNSGrant of Share Options
25th Apr 20237:00 amRNS2022 FULL YEAR RESULTS
12th Apr 20237:00 amRNSProduction Update
20th Feb 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Update
9th Jan 20237:00 amRNSMarket Update
28th Dec 20222:34 pmRNSHolding(s) in Company
14th Dec 20227:00 amRNSIofina Chemical Awarded ISO Certification
21st Nov 20227:00 amRNSChange of Adviser
28th Oct 20227:00 amRNSFinalised Terms for IO9 & Q3 Production Update
26th Sep 202211:06 amRNSSecond Price Monitoring Extn
26th Sep 202211:00 amRNSPrice Monitoring Extension
26th Sep 20227:00 amRNSInterim Results
8th Jul 20227:00 amRNSAdditional Loan Facilities and H1 Update
5th Jul 20228:54 amRNSHolding(s) in Company
22nd Jun 20222:30 pmRNSResult of AGM
20th Jun 20227:00 amRNSAppointment of Chrystal Capital Partners LLP
27th May 20227:00 amRNSNotice of AGM
26th May 20224:15 pmRNSHolding(s) in Company
26th May 20222:15 pmRNSHolding(s) in Company
24th May 20226:15 pmRNSHolding(s) in Company
20th May 20227:10 amRNSInvestor Presentation
18th May 20227:00 amRNSHolding(s) in Company
9th May 20227:00 amRNSFinal Results
5th May 20227:00 amRNSHolding(s) in Company
28th Apr 20228:38 amRNSHolding(s) in Company
19th Apr 20227:00 amRNSQ1 2022 and IO#9 Update
8th Apr 20221:07 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSDirector/PDMR Shareholding
16th Mar 20227:00 amRNSHolding(s) in Company
14th Mar 20227:00 amRNSDirector/PDMR Shareholding
11th Mar 20227:00 amRNSDirector/PDMR Shareholding
10th Mar 20227:00 amRNSDirector/PDMR Shareholding
9th Mar 20227:00 amRNSGrant of Share Options
8th Mar 20228:51 amRNSHolding(s) in Company
17th Jan 20229:00 amRNSPrice Monitoring Extension
17th Jan 20227:00 amRNSQ4 2021 Update
10th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20227:00 amRNSHolding(s) in Company
29th Dec 20217:00 amRNSBusiness Update
20th Oct 202112:44 pmRNSHolding(s) in Company
15th Oct 20217:00 amRNSQ3 2021 Update
12th Oct 20218:47 amRNSHolding(s) in Company
24th Sep 20217:00 amRNSInterim Results
23rd Sep 20214:40 pmRNSSecond Price Monitoring Extn
23rd Sep 20214:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.